Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and fluorodeoxyglucose f18

gefitinib has been researched along with fluorodeoxyglucose f18 in 16 studies

Compound Research Comparison

Studies
(gefitinib)		Trials
(gefitinib)		Recent Studies (post-2010)
(gefitinib)		Studies
(fluorodeoxyglucose f18)		Trials
(fluorodeoxyglucose f18)		Recent Studies (post-2010) (fluorodeoxyglucose f18)
5,2315662,91934,7712,16020,111

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (37.50)29.6817
2010's9 (56.25)24.3611
2020's1 (6.25)2.80

Authors

AuthorsStudies
Krohn, KA; Linden, HM; Livingston, RB; Mankoff, DA1
Bodenstein, C; Czernin, J; Dubinett, S; Dumont, RA; Herschman, H; Phelps, ME; Seimbille, Y; Su, H; Weber, W1
Akhurst, T; Kris, MG; Miller, VA; Milton, DT; Moore, E; Pao, W; Riely, GJ; Rizvi, NA; Schwartz, LH; Tyson, L; Zhao, B1
Endo, K; Hisada, T; Ishizuka, T; Kaira, K; Mori, M; Oriuchi, N; Sunaga, N; Tomizawa, Y; Yanagitani, N1
Byun, BH; Cheon, GJ; Choe, DH; Kang, HJ; Kim, CH; Koh, JS; Lee, JC; Lim, SM; Na, II; Ryoo, BY; Yang, SH1
Han, JY; Kang, KW; Kim, HT; Kim, HY; Kim, SK; Lee, DH; Lee, HY; Lee, JS; Lee, SY; Park, SH1
Goya, S; Hatazawa, J; Hirata, H; Inoue, A; Kawase, I; Kida, H; Kijima, T; Kumagai, T; Kumanogoh, A; Nagatomo, I; Okumura, M; Shimosegawa, E; Tachibana, I; Takahashi, R; Takeda, Y; Yoshida, M1
Dosaka-Akita, H; Hirata, K; Kuge, Y; Shiga, T; Takei, T; Takeuchi, S; Tamaki, N; Zhao, S; Zhao, Y1
Ando, M; Asami, K; Atagi, S; Ishii, M; Kanazu, M; Kawaguchi, T; Kubo, A; Kusunoki, Y; Maruyama, K; Matsuda, Y; Minomo, S; Ogawa, Y; Takada, M; Uehira, K1
Gao, K; Li, XY; Liang, Y; Wu, N; Zhang, LF; Zhou, LN1
Alama, A; Barletta, G; Biello, F; Boccardo, S; Bottoni, G; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Sambuceti, G; Truini, A; Vanni, I1
Chung, DH; Chung, JK; Heo, DS; Jeon, YK; Kang, KW; Keam, B; Kim, DW; Kim, TM; Lee, SH; Lee, SJ; Paeng, JC1
Buck, A; Bundschuh, R; Dandekar, G; Fecher, D; Hofmann, E; Lückerath, K; Nietzer, S; Steinke, M; Walles, H; Walles, T1
Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X1
Fukushima, T; Gomi, D; Katou, A; Kobayashi, T; Koizumi, T; Mamiya, K; Oguchi, K; Sekiguchi, N; Tateishi, K1
Kita, H; Onda, T; Yoshida, T1

Reviews

1 review(s) available for gefitinib and fluorodeoxyglucose f18

ArticleYear
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2017, Volume: 65, Issue:5

    Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome

2017

Trials

2 trial(s) available for gefitinib and fluorodeoxyglucose f18

ArticleYear
Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
    Clinical lung cancer, 2014, Volume: 15, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Treatment Outcome

2014
Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
    Medical oncology (Northwood, London, England), 2017, Sep-01, Volume: 34, Issue:10

    Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome

2017

Other Studies

13 other study(ies) available for gefitinib and fluorodeoxyglucose f18

ArticleYear
Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-01, Volume: 12, Issue:19

    Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Gefitinib; Glucose; Humans; Lung Neoplasms; Quinazolines; Radionuclide Imaging

2006
Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-01, Volume: 12, Issue:19

    Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured

2006
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-01, Volume: 13, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Tomography, X-Ray Computed

2007
Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2008, Volume: 59, Issue:2

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed

2008
18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Apr-01, Volume: 14, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome

2008
Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:7

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Predictive Value of Tests; Prospective Studies; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome

2009
Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-01, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed

2012
Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.
    BMC cancer, 2013, Nov-06, Volume: 13

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Ki-67 Antigen; Mice; Neoplasms; Phosphorylation; Quinazolines; Radiopharmaceuticals; Tumor Burden; Xenograft Model Antitumor Assays

2013
Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
    World journal of surgical oncology, 2015, Mar-15, Volume: 13

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; ROC Curve; Tissue Distribution; Tomography, X-Ray Computed; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2015
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.
    International journal of cancer, 2015, Dec-15, Volume: 137, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Signal Transduction; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays

2015
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Survival Rate

2015
Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging.
    PloS one, 2016, Volume: 11, Issue:8

    Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Fluorodeoxyglucose F18; Gefitinib; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Lung; Lung Neoplasms; Organ Culture Techniques; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Rats; Rats, Inbred Lew

2016
[Postoperative Recurrent Lung Cancer Successfully Treated with Alternate Day Administration of Gefitinib].
    Kyobu geka. The Japanese journal of thoracic surgery, 2022, Volume: 75, Issue:11

    Topics: ErbB Receptors; Exanthema; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local

2022